IMPROVED HBA1C, TOTAL DAILY INSULIN DOSE, AND TREATMENT SATISFACTION WITH INSULIN PUMP THERAPY COMPARED TO MULTIPLE DAILY INSULIN INJECTIONS IN PATIENTS WITH TYPE 2 DIABETES IRRESPECTIVE OF BASELINE C-PEPTIDE LEVELS.

Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Robert A VigerskyOpT2mise Study Group

Abstract

Fasting C-peptide levels are used to differentiate type 1 from type 2 diabetes (T2D), thereby determining eligibility for coverage of continuous subcutaneous insulin infusion (CSII) for patients with T2D. A total of 168 patients (74 female/94 male, aged 55.5 ± 9.7 years) were randomized to CSII, and 163 patients (77 female/86 male, aged 56.4 ± 9.5 years) were randomized to multiple daily injections (MDI) of insulin and grouped by baseline C-peptide level: group A (≤183 pmol/L [≤0.55 ng/mL]); group B (>183 pmol/L [>0.55 ng/mL]). At 6 months, the MDI group crossed over to CSII. Within- and between-group comparisons were recorded at 6 and 12 months in the entire group and separately for those patients aged ≥65 years. CSII reduced hemoglobin A1c (A1c) equally in groups A ( P = .0006, P = .0022) and B ( P<.0001, P<.0001) at 6 and 12 months, respectively. There was an increase in weight in group A versus group B at 6 months but not 12 months ( P<.03). CSII therapy reduced total daily dose (TDD) of insulin and improved treatment satisfaction similarly in groups A and B. The results for patients aged ≥65 years displayed a similar trend as the entire group. A1c, TDD of insulin, and treatment satisfaction improved for T2D patients using ...Continue Reading

References

Jun 10, 2008·The New England Journal of Medicine·UNKNOWN Action to Control Cardiovascular Risk in Diabetes Study GroupWilliam T Friedewald
Dec 19, 2014·Diabetes Care·Asa K DavisUNKNOWN T1D Exchange Clinic Network
Jun 8, 2017·Journal of Diabetes·Zachary Bloomgarden

❮ Previous
Next ❯

Citations

Jun 2, 2020·Journal of Diabetes Science and Technology·Guido FreckmannLutz Heinemann
Dec 22, 2019·Diabetes Care·UNKNOWN American Diabetes Association
Aug 17, 2019·Diabetes Technology & Therapeutics·Jana L WardianDarrick J Beckman
Dec 11, 2020·Diabetes Care·UNKNOWN American Diabetes Association
Sep 26, 2021·Drug Delivery and Translational Research·Shereen KesserwanUlrike Klueh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Related Papers

Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association
M MonamiE Mannucci
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Miguel N HissaLinda P Fredrickson
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Matthew C LeinungElizabeth Nardacci
© 2022 Meta ULC. All rights reserved